EX-FILING FEES 2 tm228298d2_ex-filingfees.htm EX-FILING FEES

Exhibit 107

 

Calculation of Filing Fee Table

 

424b7

(Form Type)

 

Sorrento Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

    Security
Type
  Security
Class Title
  Fee
Calculation
Rule
    Amount
Registered(1)
    Proposed
Maximum
Offering
Price Per
Unit (2)
    Maximum
Aggregate
Offering Price(2)
    Fee Rate     Amount of
Registration
Fee
 
Fees to Be Paid   Equity   Common Stock, par value $0.0001 per share     457 (c)     1,281,662     $ 2.47595     $ 3,173,331.03       0.0000927     $ 294.17 (3)
    Total Offering Amounts                       $     $ 294.17  
    Total Fees Previously Paid                                
    Total Fee Offsets                                
    Net Fee Due                             $ 294.17  

 

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock (“Common Stock”) in connection with any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock.
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) of the Securities Act.  The proposed maximum offering price per share and the proposed maximum aggregate offering price with respect to the shares are calculated based on $2.47595 per share, the average of the high and low prices of the Common Stock, as reported on the Nasdaq Capital Market on March 1, 2022, a date within five business days prior to the filing of this Registration Statement.
(3) The registration fee is calculated in accordance with Rule 457(r) of the Securities Act and represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on Form S-3ASR (Registration No. 333-261888) paid with the filing of this prospectus supplement.